TCGA-33-A5GW-01A-11R-A27Q-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- KRAS_SIGNALING_DN+0.380
- APICAL_SURFACE+0.360
- PANCREAS_BETA_CELLS+0.340
- ESTROGEN_RESPONSE_LATE+0.310
- OXIDATIVE_PHOSPHORYLATION+0.300
- MYC_TARGETS_V2+0.240
- ESTROGEN_RESPONSE_EARLY+0.230
- NOTCH_SIGNALING+0.170
- XENOBIOTIC_METABOLISM+0.170
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.530
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- IL6_JAK_STAT3_SIGNALING-0.430
- TGF_BETA_SIGNALING-0.370
- INFLAMMATORY_RESPONSE-0.360
- MITOTIC_SPINDLE-0.320
- ANGIOGENESIS-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A5UA-01A-11R-A28M-07 | — | — | 0.842 |
| 2 | TCGA-77-A5GA-01A-11R-A27Q-07 | — | cohortSQ2 | 0.834 |
| 3 | TCGA-39-5027-01A-21R-1820-07 | — | cohortSQ2 | 0.825 |
| 4 | TCGA-33-6738-01A-11R-1949-07 | — | cohortA4 | 0.821 |
| 5 | ERR3262561 | — | — | 0.821 |
| 6 | 85d43afd-9aac-48ca-a9c4-00357b7207e1 | — | — | 0.812 |
| 7 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.802 |
| 8 | ERR2278863 | — | — | 0.797 |
| 9 | SRR8613749 | — | C | 0.796 |
| 10 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.380 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.030 | Inavolisib | — uncovered |